2
Clinical Trials associated with AutoSynVax vaccine (Agenus/PureMHC)Phase 1a First-in-Human Study of Safety and Tolerability of ASV® AGEN2017 With QS-21 Stimulon® Adjuvant as a Single Agent in Subjects With Solid Tumor at Risk of Relapse Undergoing Observation as SOC Following Complete Surgical Resection
This is an open-label Phase 1a First-in-Human Study to determine Safety and Tolerability of ASV® AGEN2017 with QS-21 Stimulon® Adjuvant as a Single Agent in Subjects With Tumors at Risk of Relapse Undergoing Observation as Standard of Care Following Complete Surgical Resection.
A Phase 1 Study of Safety and Tolerability of AutoSynVax™ Vaccine as a Single Agent in Subjects With Advanced Cancer
Open-label Phase 1 study of AutoSynVax™ vaccine with QS-21 Stimulon® adjuvant in subjects with advanced cancer
100 Clinical Results associated with AutoSynVax vaccine (Agenus/PureMHC)
100 Translational Medicine associated with AutoSynVax vaccine (Agenus/PureMHC)
100 Patents (Medical) associated with AutoSynVax vaccine (Agenus/PureMHC)
100 Deals associated with AutoSynVax vaccine (Agenus/PureMHC)